FDA Watch: DOGE Changes at FDA Upend Approval Processes, Observers Say
Pre-submission and Q-Submission meetings apparently have been halted, for now
Pre-submission and Q-Submission meetings apparently have been halted, for now
The final Outpatient Prospective Payment System Final Rule for 2023 provides for a rate increase of nearly four percent.
Despite Congress’ clear policy on private insurer payment of COVID-19 tests, many labs have been struggling to get reimbursed.
Solutions you can implement right away to address current lab staffing concerns and prepare for the future.
Increasing incidences of heart disease, as well as technological advances, will drive growth over the next eight to 10 years, reports say.
According to a recent report, digital health companies are on track to rake in $21 billion for 2022, below the 2021 total of $29.1 billion.
Continuing recent patterns, M&A deal-making in the diagnostics space was low in volume but high in impact in October.
While new test approvals were scarce in October, they were particularly impactful; here are three approvals you should know about.
The Miami-based startup has secured major in-home phlebotomy services contracts from some of the nation’s biggest lab companies.
In this month’s roundup of key lab-related cases, a bizarre twist in the Theranos saga leads to a slim chance of a mistrial.
Most of the recent settlements and enforcement actions involving labs related to medically unnecessary UDTs and genetic tests.